Charles River Laboratories International, Inc. (NYSE:CRL) Short Interest Update

Charles River Laboratories International, Inc. (NYSE:CRL) was the recipient of a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 2,000,000 shares, a drop of 7.4% from the January 15th total of 2,160,000 shares. Based on an average daily volume of 785,400 shares, the short-interest ratio is currently 2.5 days.

Charles River Laboratories International Stock Performance

CRL stock traded up $2.64 on Tuesday, hitting $154.63. The company’s stock had a trading volume of 1,909,962 shares, compared to its average volume of 1,001,620. Charles River Laboratories International has a 1 year low of $150.79 and a 1 year high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock has a market cap of $7.91 billion, a price-to-earnings ratio of 19.35, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. The firm has a 50 day moving average of $174.59 and a two-hundred day moving average of $189.16.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on CRL shares. StockNews.com lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Bank of America decreased their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Evercore ISI raised their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a report on Thursday, November 7th. CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research note on Monday, November 18th. Finally, Barclays lowered their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a research note on Tuesday. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $197.64.

Hedge Funds Weigh In On Charles River Laboratories International

A number of institutional investors and hedge funds have recently made changes to their positions in CRL. Versant Capital Management Inc boosted its position in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. raised its stake in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the last quarter. Assetmark Inc. boosted its position in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares in the last quarter. Optiver Holding B.V. acquired a new stake in Charles River Laboratories International in the 4th quarter valued at about $37,000. Finally, GeoWealth Management LLC grew its stake in Charles River Laboratories International by 311.5% in the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 190 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).